Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GHB

This article was originally published in The Tan Sheet

Executive Summary

Information on abuse potential, actual abuse, medical usefulness and trafficking of gamma-hydroxybutyric acid and five other drug substances requested by FDA in an April 28 Federal Register notice. The comments will be considered by the agency in preparing a U.S. response to the World Health Organization on the abuse and diversion of the substances. WHO will use the data to consider whether to recommend certain international restrictions be placed on GHB
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS091152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel